SCHEMBL730987

SCHEMBL730987

FC(F)(F)Oc1ccc(-c2c[c]cc(-c3nnn[nH]3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 5/20 0.40
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
CYP1A2 P05177 2/20 0.37
ACP1 P24666 1/20 0.37
NOTUM Q6P988 1/20 0.36
GRK6 P43250 1/20 0.36
NISCH Q9Y2I1 1/20 0.35
NPY5R Q15761 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
WNT3A P56704 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
ALOX5 P09917 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
SMO Q99835 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL733059 0.83 NPC1 (0.40) KDM4ENPC1ALDH1A1GAAMAPT
SCHEMBL731569 0.82 F2RL3 (0.34) SCN5AKDM4ENPC1ALDH1A1GAA
SCHEMBL730958 0.81 RAB9A (0.33) KDM4ENPC1ALDH1A1MAPTRAB9A
SCHEMBL733019 0.79 MEN1 (0.39) KDM4ENPC1ALDH1A1MAPTRAB9A
SCHEMBL732981 0.72 IDO1 (0.40) KDM4ENPC1GAAMAPTRAB9A
SCHEMBL731571 0.72 NR1H2 (0.44) MAPTRAB9ANOTUMADORA2A
SCHEMBL732851 0.70 HPGD (0.43) KDM4EALDH1A1GAAMAPT
SCHEMBL5906262 0.70 NPY5R (0.46) CYP1A2NPY5RADORA2ASCN10A
SCHEMBL732877 0.69 BTK (0.34) KDM4ENPC1ALDH1A1MAPTRAB9A
SCHEMBL3328060 0.69 SCN5A (0.38) SCN5ANOTUMNISCHSCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 SCN5A 2186/4885KDM4E 3445/4885NPC1 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.